-
Mashup Score: 0EMBARK Trial Shows Promising Results for High-Risk Prostate Cancer Treatment, Enzalutamide's Impact on Metastasis-Free Survival - Neal Shore - 11 month(s) ago
Neal Shore discusses the EMBARK trial with Alicia Morgans. The study investigated whether enzalutamide plus leuprolide treatment or enzalutamide monotherapy could prolong metastasis-free survival compared with placebo plus leuprolide for men with high-risk biochemical relapse. The study’s primary endpoint was met, with patients in the combination arm showing a 58% reduction in the risk of…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0JNCCN 360 - Prostate - AUA 2023: Patients’ Preferences Take Center Stage in Study of Androgen-Deprivation Therapy - 11 month(s) ago
By: Joshua D. Madera, MS Posted: Monday, May 22, 2023 For patients with prostate cancer who are receiving androgen-deprivation therapy, the out-of-pocket cost of treatment as well as the route of administration of treatment may be among the most important attributes considered, according to a presentation given at the…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0JNCCN 360 - Prostate - AUA 2023: Update on Novel Radioligand Therapy for Castration-Resistant Prostate Cancer - 11 month(s) ago
By: Joshua D. Madera, MS Posted: Wednesday, May 24, 2023 Targeted radioligand therapy with lutetium-177–prostate-specific membrane antigen-617 (Lu-177–PSMA-617) is an efficacious treatment for patients with metastatic castration-resistant prostate carcinoma, whereas less is known about the outcomes and safety of…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Study compares outcomes for single-port vs multiport partial nephrectomy - 11 month(s) ago
“Our research focused on the outcomes at 6 months, [and we] were looking at disease recurrence and hernia occurrence,” says Jennifer Nguyen.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0
“About 80% of the patients who underwent treatment showed a very strong reduction in tryptase levels,” says Praveen Thumbikat, DVM, PhD.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0
METHOD OF PARTICIPATION:Learners will participate in this online educational activity by taking the pretest, viewing the webcast and/or listening to the podcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.Estimated time to complete this…
Source: auau.auanet.orgCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0AUA 2023 Coverage With Petros Grivas, MD, PhD - 11 month(s) ago
Highlights from the American Urological Association Annual Meeting, with a focus on bladder cancer
Source: MashupMDCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1Live from AUA2023: Highlights in BPH | AUA University - 11 month(s) ago
METHOD OF PARTICIPATION:Learners will participate in this online educational activity by taking the pretest, viewing the webcast and/or listening to the podcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.Estimated time to complete this…
Source: auau.auanet.orgCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 1Low-intensity shockwave therapy found to improve erectile dysfunction - 11 month(s) ago
“At 1 month, there was a clinically significant improvement in SHIM scoring in men that did receive the treatment vs the sham arm, which didn’t,” says Jeunice Owens-Walton, MD.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 1Dr. Rosen on the use of preoperative pregabalin for ureteroscopy - 11 month(s) ago
The data were presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
#EMBARK trial shows promising results for high-risk #ProstateCancer treatment, enzalutamide's impact on MFS. Join Neal Shore, MD, FACS @AtlanticUrology and @CaPsurvivorship @DanaFarber as they discuss on UroToday > https://t.co/LRUuRj8LiU #AUA23 @AstellasUS @pfizer https://t.co/mUUwDoZRaQ